Betmiga-Myrbetriq 50mg Extended Release

Mirabegron is a medication primarily used to treat overactive bladder (OAB), a condition characterized by urinary urgency, frequency, and incontinence. Unlike other medications used for OAB, such as anticholinergics, mirabegron works by activating beta-3 adrenergic receptors in the bladder, leading to relaxation of the bladder muscle and increased bladder capacity. By reducing the frequency and urgency of urination, mirabegron helps improve the control of bladder function and reduce episodes of urinary incontinence. It is particularly beneficial for individuals who have not responded well to or cannot tolerate other OAB medications.

One of the key features of mirabegron is its effectiveness in treating OAB symptoms while generally causing fewer anticholinergic side effects compared to traditional OAB medications. Anticholinergic medications commonly used for OAB can cause dry mouth, constipation, blurred vision, and cognitive impairment, particularly in older adults. Mirabegron offers an alternative treatment option with a more favorable side effect profile, making it suitable for a wider range of patients. Additionally, mirabegron is available in extended-release formulations, allowing for once-daily dosing, which enhances convenience and improves medication adherence.